When Compromise Becomes Infrastructure.

A compromise becomes infrastructure the same way a couch becomes part of the room. You brought it in for a reason. It fit at the time. Later you might wish it were smaller, or facing a different direction, but moving it is disruptive, and after a while you stop picturing the room without it. The couch and the room are now the same thing.

Labs accept compromises for the same reason. Each one is rational in the moment. There was a vendor limitation, or a budget constraint, or a time pressure, or a staffing gap. The compromise closed the gap. The lab moved on. And once the team has moved on, the compromise stops being a decision under review — it becomes part of the operational baseline. Future decisions get made on top of it. None of those future decisions can remove it without revisiting a conversation nobody remembers having.

The problem is that labs are systems. Every compromise reshapes what's possible downstream. A reporting workaround that saved six weeks at go-live becomes the reason a new assay takes two quarters to validate instead of one. A liquid handler that required manual loading when throughput was low becomes the reason the lab can't staff its way to higher throughput. A LIMS that was "good enough" at launch becomes the reason onboarding a new test costs six months instead of two.

None of these is catastrophic. None of them will show up in an after-action report. That's precisely why they're dangerous. They erode capability at a rate slow enough to get normalized — and the labs that feel the erosion first are always the ones trying to grow.

A clinical lab bought a new sequencer on the strength of the vendor's cost-per-sample forecast. The forecast was accurate as far as it went. What it couldn't account for was everything to the left of the sequencer — because vendors don't model what happens upstream of the instrument, and they can't. The variability across labs is too high.

This lab never implemented a LIMS. Sample tracking ran in Excel. Accessioning was paper-based. Each batch required 30 to 40 minutes of hands-on tech time just to prepare samples and reconcile paperwork, plus another window after the run to transcribe results and close out orders. They never scaled past 15 samples per week.

Had they assessed the sequencer purchase as a workflow investment rather than an instrument investment — had they paired it with a LIMS evaluation, costed hands-on time as a real line item, and modeled the downstream transcription and reporting load — they almost certainly could have delivered a profitable cost per sample. Instead, they regressed to sending specimens out.

The instrument was not the compromise. The absence of everything surrounding it was. And the absence was never visible as a decision, because nobody ever made one.

A mid-size clinical lab invested $700K in a liquid handler to eliminate the bottleneck at extraction. The platform worked. Throughput increased. The ROI model the director ran at purchase showed a clean payback inside eighteen months.

What the model didn't account for: the instrument required continuous supervision during runs. Not intervention — supervision. Someone had to be within reach in case a consumable issue, a tip failure, or an error code needed an immediate response. In practice, that meant one scientist was allocated to the liquid handler during active runs, ostensibly working on other tasks but always with one eye on the deck.

The lab didn't have a spare scientist. So on high-priority runs, it was the lab director — the person whose time is most expensive and least fungible — doing the babysitting.

The automation worked. The compromise was that the labor cost didn't come out. It just moved. The lab traded a fast-moving, visible cost (techs performing extractions by hand) for a slow-moving, invisible one (a senior scientist's attention fractured across runs, pulled off higher-value work anytime the instrument was live). The liquid handler was paying for itself on paper and quietly costing the lab its scarcest resource in practice.

A properly scoped pre-purchase evaluation would have surfaced this. The right questions are specific: Is this platform walkaway during standard operation? What error modes are recoverable without a live operator? What's the failure rate that makes unattended runs viable in this workflow? Vendors answer these questions directly when asked — but they rarely volunteer them, and they're not on the mental checklist of a lab director who has never run a liquid handler. Directors buy them. They don't operate them.

A clinical lab receives orders through the hospital's EMR. The LIMS is a separate platform. The two don't talk directly. They could, with investment — the integration was scoped once — but it was deprioritized at the time the LIMS was stood up. The accessioning team closed the gap by manually transcribing order information from the EMR screen into the LIMS. Phase two would solve it later.

At low volume, the workaround was tolerable. At current volume, it consumes hours per day across the accessioning team. More importantly: every manual transcription is a regulatory liability. Patient identifiers, order codes, specimen types — every field keyed by a human is a field that can be miskeyed. The lab has good quality controls. It catches most errors. It does not catch all of them.

The compromise here is double-headed. There's the time cost, which is quantifiable and erodes slowly. There's the regulatory risk, which is harder to quantify and potentially catastrophic. Both were accepted at the time the LIMS was implemented, because the integration was "phase two." Phase two arrived, and then the team had other priorities, and phase two became never.

Nobody in the lab is unaware of this gap. It's discussed. It's on the roadmap. What it isn't, is costed. Nobody has ever put a number on the accessioning hours consumed by transcription or quantified the regulatory exposure the manual workflow creates. Until someone does, the integration loses every prioritization battle against whatever else is urgent this month. It will keep losing indefinitely.

You'll notice something about those three stories. None of the compromises is, by itself, a scandal. Each one has a plausible-sounding justification. Each one fit the operational reality at the moment it was made. They compound anyway. Here's why.

A compromise, once accepted, stops being visible. It's no longer a decision under review. It's the shape of the floor the lab walks on. Every subsequent decision gets made on top of it — which means every subsequent decision inherits the compromise's constraints without anyone naming them.

The lab that regressed to send-out didn't lose the money on a single bad decision. It lost it across every subsequent workflow choice that assumed manual sample tracking was viable — because manual sample tracking was already the floor. The lab with the $700K babysitter didn't lose the scientist's time on day one. It lost it across every month where "babysit the liquid handler" was already in the operational baseline and nobody thought to question it. The lab bridging EMR and LIMS by hand didn't incur a regulatory risk on a single day. It incurred it across every order processed by a human keyboard over three years.

"The real cost of normalized compromise isn't the loss. It's the invisibility of the loss. And invisible losses don't get fixed, because nobody has a reason to fix them."

This is the compounding mechanism. The compromise doesn't grow — the lab just grows around it. And the stack of them, accumulated quietly over years, becomes the real ceiling on what the lab can do next.

If you read those five steps and thought "that's product manager work," you're right. It is.

Current-state mapping, gap analysis, sequencing, roadmapping, business-case framing — these are the core operating verbs of a software product manager. They're also exactly the right verbs for auditing a lab's operational infrastructure. The translation between the two domains is nearly one-to-one.

Most labs don't have a product manager, and they probably shouldn't hire one full-time. The shape is rare and the utilization is uneven. Labs have a director who's running the operation, an IT lead keeping the systems up, and in some cases a bioinformatician keeping pipelines running. None of those people have spare cycles to do a structural audit of the lab's normalized compromises — even though any of them could recognize the findings once they were named.

The capability is rare because it sits at the intersection of lab operations, IT architecture, regulatory environment, and business strategy. People who have that range tend to be running product organizations at life science software companies, not working inside clinical labs. Which is why fractional engagements exist — to bring that shape to a lab for a defined window, produce the audit and the roadmap, and leave the execution to the team that has to own it going forward.